Claims for Patent: 7,776,525

Summary for Patent: 7,776,525

Title:	Method of diagnosing disease relating to endometriosis
Abstract:	The expression level of a histamine-releasing factor (HRF) polynucleotide in a biological sample of a subject is measured and the HRF polynucleotide content is compared with that of a normal biological sample. An HRF polynucleotide expression level considerably higher than that of the normal biological sample is employed as an indication of a disease relating to endometriosis or a risk thereof.
Inventor(s):	Kuroda; Masahiko (Tokyo, JP), Oikawa; Kosuke (Tokyo, JP), Kosugi; Yoshinori (Tokyo, JP), Ohbayashi; Tetsuya (Kyoto, JP)
Assignee:	Japanese Science and Technology Agency (Saitama, JP)
Application Number:	10/564,481
Patent Claims:	1. A method for diagnosing endometriosis in a human, said method comprises: (a) measuring an expression level of histamine releasing factor (HRF) polynucleotide in a biological sample from a human subject wherein said biological sample is menstrual blood; and (b) comparing the HRF polynucleotide expression level with that in a normal biological sample, wherein a subject exhibiting a higher polynucleotide expression level when compared with the normal biological sample is indicative of a subject having endometriosis or a subject at risk thereof. 2. A method for diagnosing endometriosis in a human, said method comprising: (a) preparing RNA from a biological sample of a human subject, wherein said biological sample is menstrual blood; (b) subjecting the RNA prepared in step (a) to an electrophoretic separation; (c) hybridizing the RNA prepared in step (b) with a labeled HRF oligonucleotide probe that hybridizes under a stringent condition with HRF polynucleotide; (d) comparing the signal level of the labeled HRF oligonucleotide probe which hybridized with the RNA in step (c) as an index of the HRF polynucleotide expression level with a result of a normal biological sample; and, (e) using a higher HRF polynucleotide expression level when compared with the normal biological sample as a index reflecting, the degree of endometriosis or risk thereof. 3. A method for diagnosing endometriosis in a human, said method comprising: (a) preparing RNA from a biological sample of a human subject, wherein said biological sample is menstrual blood; (b) preparing a labeled cDNA from the RNA prepared in step (a); (c) contacting the labeled cDNA prepared in step (b) with a DNA microarray having as a target capture probe an HRF polynucleotide or an HRF oligonucleotide that hybridizes under a stringent condition with HRF polynucleotide; (d) comparing the signal level of the labeled cDNA which hybridized with the capture probe of the DNA microarray in step (c) as an index of the HRF polynucleotide expression level with a result of a normal biological sample; and, (e) using a higher HRF polynucleotide expression level when compared with the normal biological sample as a index reflecting, the degree of endometriosis or risk thereof. 4. A method for diagnosing endometriosis, said method comprising: (a) preparing RNA from a biological sample of a human subject, wherein said biological sample is menstrual blood; (b) synthesizing a cDNA using a primer set for PCR amplification of an HRF polynucleotide with the RNA prepared in step (a) as a template; (c) comparing the level of the cDNA prepared in step (b) as a HRF polynucleotide expression index with a result of a normal biological sample; and, (d) using a higher HRF polynucleotide expression level when compared with the normal biological sample as a index reflecting the degree of endometriosis or risk thereof.

Details for Patent 7,776,525

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2023-07-14